VXRT Vaxart Inc

Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") announced today that management will host a conference call on Monday, February 10, 2014 at 9:00a.m EST to review the Company's second quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call.

Webcast Information

To access the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international). A live audio webcast of the call and the archived webcast will be available in the Investors section of the Biota website at http://www.biotapharma.com.

About Biota

Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV). In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV). For additional information about the Company, please visit www.biotapharma.com.

Biota is a registered trademark of Biota Holdings Limited. 

CONTACT: Russell H. Plumb
         President & CEO
         (678) 221-3351
         r.plumb@biotapharma.com
         
         Lee M. Stern
         The Trout Group
         lstern@troutgroup.com